FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080784805> ?p ?o ?g. }

• W2080784805 endingPage "164" @default.
• W2080784805 startingPage "157" @default.
• W2080784805 abstract "Background In recent years there has been considerable interest in reducing the duration of antibiotic treatment regimens in patients with common bacterial infections. We conducted two independent, investigator-blinded, multicenter, randomized clinical trials, one of which included microbiologic evaluation of middle ear fluid obtained by tympanocentesis, comparing the efficacy and safety of 5 or 10 days of treatment with cefuroxime axetil suspension (CAE) with that of 10 days of treatment with amoxicillin/clavulanate suspension (AMX/CL) in children with acute otitis media. Methods A total of 719 pediatric patients from the ages of 3 months to 12 years were enrolled in the 2 studies. Patients received CAE for either 5 or 10 days at 30 mg/kg/day in 2 divided doses (n = 242 and 235, respectively) or AMX/CL for 10 days at 40 mg/kg/day in 3 divided doses (n = 242). Patients in the CAE (5 days) group received placebo on Days 6 through 10. In the study that included tympanocentesis, bacteriologic assessments were based on middle ear fluid cultures obtained pretreatment and, when possible, after treatment in patients with an unsatisfactory clinical outcome. Results Organisms were isolated from the pretreatment middle ear fluid specimens of 177 of 244 (73%) patients undergoing tympanocentesis, with the primary pathogens being Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis (37, 35 and 12% of isolates, respectively). Pathogens were eradicated or presumed to be eradicated in 92% (24 of 26), 84% (32 of 38) and 95% (36 of 38) of bacteriologically evaluable patients treated with CAE for 5 or 10 days or with AMX/CL, respectively. A satisfactory clinical outcome (cure or improvement) occurred in 69% (101 of 147), 70% (121 of 173) and 74% (131 of 177) of clinically evaluable patients treated with CAE (5 days), CAE (10 days) or AMX/CL, respectively. Treatment with AMX/CL was associated with a significantly higher incidence of drug-related adverse events than was treatment with CAE for either 5 or 10 days (P < 0.001), primarily reflecting a higher incidence of drug-related gastrointestinal adverse events (34% vs. 17 and 12%, respectively; P < 0.001), particularly diarrhea. Conclusions Treatment with CAE given twice daily for 5 days is equivalent to treatment for 10 days either with the same regimen of CAE or with AMX/CL given three times daily in pediatric patients with acute otitis media." @default.
• W2080784805 created "2016-06-24" @default.
• W2080784805 creator A5002557162 @default.
• W2080784805 creator A5024812667 @default.
• W2080784805 creator A5033651436 @default.
• W2080784805 creator A5034849279 @default.
• W2080784805 creator A5035650443 @default.
• W2080784805 creator A5057600735 @default.
• W2080784805 creator A5062535677 @default.
• W2080784805 creator A5068133313 @default.
• W2080784805 creator A5073880645 @default.
• W2080784805 creator A5085766263 @default.
• W2080784805 date "1996-02-01" @default.
• W2080784805 modified "2023-10-18" @default.
• W2080784805 title "Effectiveness of five days of therapy with cefuroxime axetil suspension for treatment of acute otitis media" @default.
• W2080784805 cites W124005684 @default.
• W2080784805 cites W1967571838 @default.
• W2080784805 cites W1970792094 @default.
• W2080784805 cites W1975582762 @default.
• W2080784805 cites W1984883296 @default.
• W2080784805 cites W1993220990 @default.
• W2080784805 cites W2014335701 @default.
• W2080784805 cites W2015045556 @default.
• W2080784805 cites W2029820126 @default.
• W2080784805 cites W2056315202 @default.
• W2080784805 cites W2075292748 @default.
• W2080784805 cites W2081200134 @default.
• W2080784805 cites W2092243959 @default.
• W2080784805 cites W2099341493 @default.
• W2080784805 cites W2120110437 @default.
• W2080784805 cites W2159189010 @default.
• W2080784805 cites W2163920914 @default.
• W2080784805 doi "https://doi.org/10.1097/00006454-199602000-00013" @default.
• W2080784805 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8822290" @default.
• W2080784805 hasPublicationYear "1996" @default.
• W2080784805 type Work @default.
• W2080784805 sameAs 2080784805 @default.
• W2080784805 citedByCount "65" @default.
• W2080784805 countsByYear W20807848052012 @default.
• W2080784805 countsByYear W20807848052014 @default.
• W2080784805 countsByYear W20807848052015 @default.
• W2080784805 countsByYear W20807848052016 @default.
• W2080784805 countsByYear W20807848052017 @default.
• W2080784805 countsByYear W20807848052019 @default.
• W2080784805 countsByYear W20807848052020 @default.
• W2080784805 countsByYear W20807848052023 @default.
• W2080784805 crossrefType "journal-article" @default.
• W2080784805 hasAuthorship W2080784805A5002557162 @default.
• W2080784805 hasAuthorship W2080784805A5024812667 @default.
• W2080784805 hasAuthorship W2080784805A5033651436 @default.
• W2080784805 hasAuthorship W2080784805A5034849279 @default.
• W2080784805 hasAuthorship W2080784805A5035650443 @default.
• W2080784805 hasAuthorship W2080784805A5057600735 @default.
• W2080784805 hasAuthorship W2080784805A5062535677 @default.
• W2080784805 hasAuthorship W2080784805A5068133313 @default.
• W2080784805 hasAuthorship W2080784805A5073880645 @default.
• W2080784805 hasAuthorship W2080784805A5085766263 @default.
• W2080784805 hasConcept C126322002 @default.
• W2080784805 hasConcept C141071460 @default.
• W2080784805 hasConcept C142724271 @default.
• W2080784805 hasConcept C204787440 @default.
• W2080784805 hasConcept C27081682 @default.
• W2080784805 hasConcept C2776439223 @default.
• W2080784805 hasConcept C2776551000 @default.
• W2080784805 hasConcept C2776925733 @default.
• W2080784805 hasConcept C2777514703 @default.
• W2080784805 hasConcept C2779708577 @default.
• W2080784805 hasConcept C2781253189 @default.
• W2080784805 hasConcept C501593827 @default.
• W2080784805 hasConcept C71924100 @default.
• W2080784805 hasConcept C86803240 @default.
• W2080784805 hasConcept C89423630 @default.
• W2080784805 hasConcept C90924648 @default.
• W2080784805 hasConceptScore W2080784805C126322002 @default.
• W2080784805 hasConceptScore W2080784805C141071460 @default.
• W2080784805 hasConceptScore W2080784805C142724271 @default.
• W2080784805 hasConceptScore W2080784805C204787440 @default.
• W2080784805 hasConceptScore W2080784805C27081682 @default.
• W2080784805 hasConceptScore W2080784805C2776439223 @default.
• W2080784805 hasConceptScore W2080784805C2776551000 @default.
• W2080784805 hasConceptScore W2080784805C2776925733 @default.
• W2080784805 hasConceptScore W2080784805C2777514703 @default.
• W2080784805 hasConceptScore W2080784805C2779708577 @default.
• W2080784805 hasConceptScore W2080784805C2781253189 @default.
• W2080784805 hasConceptScore W2080784805C501593827 @default.
• W2080784805 hasConceptScore W2080784805C71924100 @default.
• W2080784805 hasConceptScore W2080784805C86803240 @default.
• W2080784805 hasConceptScore W2080784805C89423630 @default.
• W2080784805 hasConceptScore W2080784805C90924648 @default.
• W2080784805 hasIssue "2" @default.
• W2080784805 hasLocation W20807848051 @default.
• W2080784805 hasLocation W20807848052 @default.
• W2080784805 hasOpenAccess W2080784805 @default.
• W2080784805 hasPrimaryLocation W20807848051 @default.
• W2080784805 hasRelatedWork W173725712 @default.
• W2080784805 hasRelatedWork W1967186914 @default.
• W2080784805 hasRelatedWork W2006783234 @default.
• W2080784805 hasRelatedWork W2047552238 @default.

• next